Safety and Efficacy of AIN457 in Noninfectious Uveitis

Status:
Completed

Trial end date:
2013-09-01

Target enrollment:

Participant gender:

This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.

Phase 2

Novartis Pharmaceuticals

Antibodies, Monoclonal